





Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SUBSTITUTE FOR FORM 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: August 9, 2002  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	09/787,111
		Filing Date	05/14/2001
		First Named Inventor	Louis SCHOFIELD
		Group Art Unit	1614
		Examiner Name	Unassigned
Sheet 2 of 2		Attorney Docket Number	017227-0172

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A9	SCHOFIELD ET AL., "Signal transduction in host cells mediated by glycosylphosphatidylinositols of the parasitic protozoa, or why do the parasitic protozoa have so many GPI molecules?," <i>Brazilian J. Med. Biol. Res.</i> (1994), Vol. 27, pp. 249 – 254.	
	A10	MCCONVILLE ET AL., "The structure, biosynthesis and function of glycosylated phosphatidylinositols in the parasitic protozoa and higher eukaryotes," <i>Biochem. J.</i> (1993), Vol. 294, pp. 305 – 324, Great Britain.	
	A11	ELHAY ET AL., "Lipophosphoglycan expression and virulence in Ricin-resistant variants of leishmania major," <i>Molecular and Biochemical Parasitology</i> (1990), Vol. 40, pp. 255 – 268, Elsevier Science Publishers B.V. (Biomedical Division).	
	A12	MISEK ET AL., "An Inositol Phosphate Glycan Derived from a <i>Trypanosoma brucei</i> Glycosyl-Phosphatidylinositol Mimics some of the Metabolic Actions of Insulin," <i>The Journal of Biological Chemistry</i> (August 15, 1992), Vol. 267, No. 23, pp. 16266 16273, The American Society for Biochemistry and Molecular Biology, Inc.	


Examiner Signature		Date Considered	5/15/03
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08 (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: August 9, 2002 (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/787,111
Sheet	1	of	2	Filing Date	05/14/2001
				First Named Inventor	Louis SCHOFIELD
				Group Art Unit	1614
				Examiner Name	Unassigned
				Attorney Docket Number	017227-0172

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
mm	A1	AU	65674/94		REUTTER ET AL.	12/22/1994		X

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>	
mm	A2	GEROLD ET AL., "Structural analysis of the glycosyl-phosphatidylinositol membrane anchor of the merozoite surface proteins-1 and -2 of <i>Plasmodium falciparum</i> ," <i>Molecular and Biochemical Parasitology</i> (1996), Vol. 75, pp. 131-143, Elsevier Science B.V.		
	A3	SCHOFIELD ET AL., "Neutralizing monoclonal antibodies to glycosylphosphatidylinositol, the dominant TNF- $\alpha$ -inducing toxin of <i>Plasmodium falciparum</i> : prospects for the immunotherapy of severe malaria," <i>Annals of Tropical Medicine and Parasitology</i> (1993), Vol. 87, No. 6, pp. 617-626, Liverpool School of Tropical Medicine.		
mm	A4	RICHARDSON ET AL., "Native and baculovirus-expressed forms of the immuno-protective protein BM86 from <i>Boophilus microplus</i> are anchored to the cell membrane by a glycosyl-phosphatidyl inositol linkage," <i>Insect Molecular Biology</i> (1993), Vol. 1, No. 3, pp. 139 – 147.		
mm	A5	SCHOFIELD ET AL., "Regulation of host cell function by glycosylphosphatidylinositols of the parasitic protozoa," <i>Immunology and Cell Biology</i> (1996), Vol. 74, pp. 555 – 563.		
mm	A6	SCHOFIELD ET AL., "Signal Transduction in Host Cells by a Glycosylphosphatidylinositol Toxin of Malaria Parasites," <i>J. Exp. Med.</i> (January 1993), Vol. 177, pp. 145 – 153, The Rockefeller University Press.		
mm	A7	TACHADO ET AL., "Signal transduction in macrophages by glycosylphosphatidylinositols of <i>Plasmodium</i> , <i>Trypanosoma</i> , and <i>Leishmania</i> : Activation of protein tyrosine kinases and protein kinase C by inositolglycan and diacylglycerol moieties," <i>Proc. Natl. Acad. Sci.</i> (April 1997), Vol. 94, pp. 4022 – 4027, The National Academy of Sciences of the USA.		
mm	A8	REYMOND ET AL., "Anchoring of an Immunogenic <i>Plasmodium falciparum</i> Circumsporozoite Protein on the Surface of <i>Dictyostelium discoideum</i> ," <i>The Journal of Biological Chemistry</i> (1995), Vol 270, No. 21, 12941 – 12947.		

Examiner Signature	<i>N. M. Schofield</i>	Date Considered	5/15/2001
--------------------	------------------------	-----------------	-----------

\*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance. And not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

RECEIVED  
AUG 14 2001  
TECH CENTER  
1600 900